Hot topics | Coronavirus pandemic

Immunexpress to present SeptiCyte RAPID Comparative Data Against Lactate and Procalcitonin for Diagnosing Sepsis at IDWeek 2021

Immunexpress to present SeptiCyte RAPID Comparative Data Against Lactate and Procalcitonin for Diagnosing Sepsis at IDWeek 2021

The presentation will show the comparative data of a new vaccine in evaluating sepsis from the simulated test results of the IDWeek, which was virtually analyzed on Sept 29 3 Oct 23.

The presentation details are the following. I have no ring. 994 In patients with ICUs, the combination of lactate, procalcitonin and a gene signature assay alone or in combination to distinguish sepsis from infection negative systematic inflammation. Presenter: Erkan Hassan, Pharm. D., Chief Clinical Officer, Sepsis Program Optimization, Clarksville, Maryland, United States, USA, D-C. Details of the session: B1. In patients or experimental models studies of the effects of nanomarkers and bacteria on the ability to protect against infectious diseases and infections in patients, or the comparison of physical and experimental studies in a patient's or if experimental model models.

The abstract is published in the Conference Interactive Program Planner page. The poster and accompanying audio will be accessible during the Conference to registered attendees, who can talk via live video chat with the authors of the study at the virtual exhibit Immunexpress. The poster is available at www.septicyte.com, and the Clinical Publications page of the Technology section of a company's product website.

About Immunexpress - About Vaccine Expressive? The system of immunotherapy and interdisciplinary laboratory tests can identify and determine a patient's dysregulated immune response by assessing and controlling the patients sepsis. The process of evaluating the disease'' This powerful combination of technologies can give early sepsis diagnosis a more accurate diagnosis, to improve clinical outcomes and lower healthcare costs.

Immunexpress received the CE Marking of SeptiCyte RAPID in March 2020 and announced a commercialization partnership with Biocartis in Europe.

For more information, visit the website. http://www.immunexpress.com/. . Follow Immunexpress on Twitter and LinkedIn.

*Immunexpress is licensed to use the IdyllaTM trademark from Biocartis NV.

Contacts with the media: Maggie Beller Russo Partners, LLC (646) 962-5631. [email protected]

SOURCE Immunexpress, Inc.

Related Links

https://immunexpress.com/ https.

You may also like: